1093070-14-4

1093070-14-4 structure

Name: PLpro inhibitor
Chemical Name: 5-acetamido-2-methyl-N-(2-naphthalen-1-ylethyl)benzamide
CAS Number: 1093070-14-4
Molecular Formula: C₂₂H₂₂N₂O₂
Molecular Weight: 346.42200
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2018-12-25 21:32:31
Modify Date: 2024-01-03 09:00:12
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 uM.IC50 Value: 2.6 uM [1]Target: PLpro; SARS-CoVin vitro: PLpro inhibitor is a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). PLpro inhibitor was found to have IC50 value of 2.6 ± 0.1 μM. PLpro inhibitor display significant antiviral activity with EC50 values of 13.1±0.7 uM, without toxicity up to the highest concentration tested. Notably, the increasing antiviral potency correlates with the in vitro inhibition of PLpro, suggesting that the compounds work directly on the enzyme in cells [1,2].in vivo:

Name	5-acetamido-2-methyl-N-(2-naphthalen-1-ylethyl)benzamide
Synonyms	5-acetamido-2-methyl-N-[2-(1-naphthalenyl)ethyl]benzamide PLpro inhibitor 5-acetylamino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide I06-1404 5-N-Acetylamino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide

Description	PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 uM.IC50 Value: 2.6 uM [1]Target: PLpro; SARS-CoVin vitro: PLpro inhibitor is a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). PLpro inhibitor was found to have IC50 value of 2.6 ± 0.1 μM. PLpro inhibitor display significant antiviral activity with EC50 values of 13.1±0.7 uM, without toxicity up to the highest concentration tested. Notably, the increasing antiviral potency correlates with the in vitro inhibition of PLpro, suggesting that the compounds work directly on the enzyme in cells [1,2].in vivo:
Related Catalog	Signaling Pathways >> Anti-infection >> SARS-CoV Research Areas >> Infection
References	[1]. Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. [2]. http://www.google.com/patents/WO2010022355A1cl=en